Faculty

Back to Index
Leonardo C Clavijo, MD, PhD
Associate Professor of Clinical Medicine
Director, Interventional Cardiology Fellowship Program
Medicine
HCC 300N Health Sciences Campus Los Angeles
+1 323 442 6130

Overview

Dr. Clavijo's clinical interests include non-surgical treatment of complex vascular disease, peripheral arterial disease, peripheral vascular disease, carotid disease and interventional cardiology. His research interests include percutaneous coronary interventions, critical limb ischemia, endovascular treatment of peripheral arterial and venous vascular disease and vascular biology.

Dr. Clavijo earned his medical degree from Universidad Nacional de Colombia. He then went on to complete his Masters of Science in Physiology & Biophysics and Doctor of Philosophy in Physiology & Biophysics from the University of Louisville School of Medicine.

Publications

Computerized tomography angiography by direct intra-aortic low volume contrast injection in patients being evaluated for EVAR. Vascular. 2017 Jan 01; 1708538117690662. View in: PubMed

Association of elevated triglycerides and acute myocardial infarction in young Hispanics. Cardiovasc Revasc Med. 2016 Dec; 17(8):510-514. View in: PubMed

Increased risk of mortality after lower extremity bypass in individuals with acute kidney injury in the Vascular Quality Initiative. J Vasc Surg. 2016 Nov 16. View in: PubMed

Same-day discharge after coronary stenting and femoral artery device closure: A randomized study in stable and low-risk acute coronary syndrome patients. Cardiovasc Revasc Med. 2016 Apr-May; 17(3):155-61. View in: PubMed

Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovasc Revasc Med. 2015 Dec; 16(8):450-4. View in: PubMed

Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. 2015 Mar; 20(2):144-56. View in: PubMed

Vascular disease. Cardiol Clin. 2015 Feb; 33(1):ix. View in: PubMed

Critical limb ischemia. Cardiol Clin. 2015 Feb; 33(1):37-47. View in: PubMed

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. J Thromb Thrombolysis. 2015 Jan; 39(1):8-14. View in: PubMed

African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention. Cardiovasc Revasc Med. 2014 Jun; 15(4):214-8. View in: PubMed

Use of regadenoson for measurement of fractional flow reserve. Catheter Cardiovasc Interv. 2014 Feb 15; 83(3):369-74. View in: PubMed

Recalcitrant peroneal artery pseudoaneurysm in a patient with Hemophilia B. Cardiovasc Revasc Med. 2013 Nov-Dec; 14(6):359-62. View in: PubMed

Cardiovascular pharmacology core reviews: aspirin. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):505-13. View in: PubMed

Devices to treat peripheral chronic total occlusions. J Interv Cardiol. 2012 Aug; 25(4):395-403. View in: PubMed

Percutaneous left ventricular support for high-risk PCI and cardiogenic shock: who gets what? Cardiovasc Revasc Med. Percutaneous left ventricular support for high-risk PCI and cardiogenic shock: who gets what? Cardiovasc Revasc Med. 2012 Mar; 13(2):101-5. View in: PubMed

Percutaneous devices to support the left ventricle. Expert Rev Med Devices. 2011 Nov; 8(6):681-94. View in: PubMed

Acute ST segment elevation during exercise stress echocardiography due to severe pulmonary hypertension. Cardiovasc Ultrasound. 2011; 9:18. View in: PubMed

Cerebral vasospasm and concurrent left ventricular outflow tract obstruction: requirement for modification of hyperdynamic therapy regimen. Neurocrit Care. 2010 Apr; 12(2):265-8. View in: PubMed

Use of drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction. J Invasive Cardiol. 2009 Nov; 21(11):E206-12. View in: PubMed

Revascularization of carotid stenosis before cardiac surgery. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1393-6. View in: PubMed

Interanimal variability in preexisting collaterals is a major factor determining outcome in experimental angiogenesis trials. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1891-7. View in: PubMed

Comparison of clinical outcomes of overlapping sirolimus- versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2006 Dec 15; 98(12):1563-6. View in: PubMed

Sirolimus-eluting stents and calcified coronary lesions: clinical outcomes of patients treated with and without rotational atherectomy. Catheter Cardiovasc Interv. 2006 Dec; 68(6):873-8. View in: PubMed

Comparison of paclitaxel-eluting stent and sirolimus-eluting stent expansion at incremental delivery pressures. Cardiovasc Revasc Med. 2006 Oct-Dec; 7(4):208-11. View in: PubMed

Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006 Jul 15; 98(2):187-92. View in: PubMed

Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovasc Revasc Med. 2006 Jul-Sep; 7(3):132-5. View in: PubMed

Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006 Jul; 68(1):62-6. View in: PubMed

Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol. 2006 Apr 1; 97(7):981-3. View in: PubMed

Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol. 2006 Apr; 19(2):121-5. View in: PubMed

Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006 Apr; 67(4):595-9. View in: PubMed

Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2006 Mar 15; 97(6):792-7. View in: PubMed

Impact of three or more versus a single sirolimus-eluting stent on outcomes in patients who undergo percutaneous coronary intervention. Am J Cardiol. 2006 Mar 1; 97(5):606-10. View in: PubMed

Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006 Feb 28; 113(8):1108-13. View in: PubMed

Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med. 2006 Jan-Mar; 7(1):7-11. View in: PubMed

Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients. Am J Cardiol. 2005 Oct 15; 96(8):1100-6. View in: PubMed

Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. Cardiovasc Revasc Med. 2005 Oct-Dec; 6(4):154-9. View in: PubMed

The potential role of resistin in atherogenesis. Atherosclerosis. 2005 Oct; 182(2):241-8. View in: PubMed

Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol. 2005 Oct; 46(4):481-6. View in: PubMed

Sudden cardiac death in athlete with anomalous single coronary artery. Cardiovasc Revasc Med. 2005 Apr-Jun; 6(2):89-90. View in: PubMed

MRI evaluation of a coronary artery perforation. Cardiovasc Revasc Med. 2005 Jan-Mar; 6(1):44-5. View in: PubMed

"Hybrid" approach for the treatment of a giant left main coronary artery aneurysm. Cardiovasc Radiat Med. 2004 Jul-Sep; 5(3):153-4. View in: PubMed

Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. 2004 Jun 15; 109(23):2826-31. View in: PubMed

Powered bySC CTSI